G- Competitors seem to be LASE, BOL, SNRS, and BEAM (which used to be in partnership w/VISX until the FDA decided the two were illegally controlling the market).
SNRS got a boost this week (and VISX a black eye) by FDA approval (after an earlier disapproval) of their solution, which involves melting rather than cutting and takes just 3 seconds. The market failed to focus (ha!) on the fact that, in an indeterminate amount of cases, the improvement is only temporary and SNRS' literature would have to state that fact.
My dd focused on the causes of the recent downtrend, and is the market's judgement correct vis a vis the Nidek suit? I believe not.
Nidek has a 'smooth scan' technology; which I believe to be relatively primitive (VISX uses broad beam ablation), and not where the market is headed, which is custom ablation.
Their distribution is poor and prospective clients fear of litigation will also be a factor in their eventual defeat in the marketplace (VISX sues the doctors as well); and that's beside the fact that I believe VISX's case will prove far the stronger in court (real court in Northern California, not just an initial ITC ruling).
That also leaves out the possibility (probability?)of BOL and LASE licensing VISX technology.
As I generally hate betting against the market, anything you can add to bolster my basic understanding, or even prove me wrong, would be great. |
